Upadacitinib
Rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis and more
- CAS No.
- 1310726-60-3
- Indication Class
- Immunology / Inflammation
- Patent Expiry
- To be assessed
- Therapeutic Area
- Autoimmune / Rheumatology
- Target / Mechanism
- JAK1·JAK2·JAK3·TYK2
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 8 key intermediates available
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid | 1428243-24-6 | — | |
| (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester | 1428243-26-8 | — | |
| 1-[(benzyloxy)carbonyl]-4-ethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid | 1869118-25-1 | — | |
| 5-Bromo-4,7-diazaindole | 875781-43-4 | — | |
| 8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine | 1428243-28-0 | — | |
| N-[5-[(4-Methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]carbamic acid ethyl ester | 1869118-24-0 | — | |
| N-Tosyl-5-bromo-4,7-diazaindole | 1201186-54-0 | — | |
| tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate | 1201187-44-1 | — |
Listing Logic · Why It's Worth Listing
A leading oral targeted therapy in autoimmunity spanning rheumatology, dermatology and gastroenterology, with strong and definable volume upside.
Autoimmune / Rheumatology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
8 key intermediates available; scale-up and cost control manageable
Product Description
Upadacitinib is an oral, targeted medication used to treat several moderate-to-severe autoimmune and inflammatory conditions. It belongs to a class of drugs called JAK inhibitors and is specifically designed to selectively target the JAK1 enzyme, a key driver of inflammation.
Supply source: Unibest · Upadacitinib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.